EUCTR2013-003660-31-IE进行中（未招募）1 期
A Phase 2b, Randomized, Double-Blind, PLacebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Potential study participants must meet the following entry criteria:
- •Age 18 to 80 years
- •Physician-diagnosed celiac disease patients with documented history of biopsy-proven celiac disease; patients previously diagnosed only by positive serology and clinical response to exclusion of dietary gluten will require biopsy confirmation of celiac disease prior to randomization at Visit 4
- •Self-reported to be on a gluten-free diet (GFD) for at least 11 months prior to enrollment at Visit 2; patients attempting adherence to a GFD who previously participated in Alvine Study ALV003-1121 may be eligible if they otherwise meet entry criteria
- •Experienced at least one self-reported moderate or severe symptom included in the CDSD©, probably/likely as a result of gluten exposure, during the 28-day period prior to screening
- •Have daily telephone access in order to complete the CDSD©
- •Agree to maintain dosing of approved prescribed and OTC medications throughout the course of the study
- •Willing to take study treatment three times each day with each gluten-free major meal, with minimal ingestion outside of these meals
- •Willing to undergo two (2) on-study upper gastrointestinal endoscopies with duodenal biopsies
- •Willing and able to comply with all study procedures
- •Sign informed consent
- •Must read and understand native language of their country
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Potential study participants must NOT meet any of the following criteria:
- •History of known Immunoglobulin E (IgE)-mediated reaction to wheat (i.e., wheat allergy”)
- •Currently untreated or active: peptic ulcer disease, esophagitis (Los Angeles Classification = Grade C), irritable bowel syndrome, inflammatory bowel disease, or microscopic colitis
- •Active dermatitis herpetiformis
- •Patients with known rapid gastric emptying (e.g., post-bariatric surgery, Billroth I or II surgery)
- •Chronic infectious gastrointestinal illness, or acute infectious gastrointestinal illness within the 4 week period prior to enrollment
- •Known Refractory Celiac Disease (RCD1 or RCD2). RCD is characterized by persistent symptoms, severe malabsorption, and intestinal damage despite strict adherence to a GFD (in patients with RCD 1, the intraepithelial lymphocyte phenotype is normal; in RCD 2, there is a clonal aberrant phenotype of the intraepithelial lymphocyte)
- •Screening laboratory values
- •a.Elevated liver function tests (Alanine Aminotransferase [ALT], Aspartate Transaminase [AST], Alkaline Phosphatase [Alk Phos], or Gamma-Glutamyl Transferase [GGT]) > 2.5x ULN
- •b.Total bilirubin > 2x ULN
- •c.Serum creatinine > 1.5x ULN
- •d.Calcium < 8.0 mg/dL
- •e.Serum potassium < 3.0 mEq/L, > 5.5 mEq/L
- •f.Hemoglobin < 8.5 g/dL
- •g.Platelet count < 75.0 x 10^9/L or 75,000/mm3
- •h.Total white blood cell count (WBC) < 2.5 x 10^9/L or 2500/mm3
- •i.Total lymphocyte < 0.8 x 10^9/L or 800/mm3
- •For women of childbearing potential, positive pregnancy test at screening, or planning to become pregnant during the course of the study, or unwilling to practice effective birth control during the study
- •Expected use of anticoagulants or antiplatelet agents (e.g., warfarin, heparin, or clopidogrel or similar class), other than mini-dose (e.g., 81 mg aspirin), during the week prior to intestinal biopsies that, in the opinion of the endoscopist, would affect the safety of obtaining the biopsies
- •Change of dose or frequency of systemic glucocorticosteroid medications, oral budesonide, or mesalamine within 28-days prior to enrollment at Visit 2 and/or expected to change during the study
- •Use of angiotensin II receptor blockers (ARBs) within 28 days prior to enrollment at Visit 2 and during the study
- •History of alcohol abuse or habitual use of illicit drugs (e.g., amphetamines, barbiturates, benzodiazepines, cocaine, and opiates, including abuse of prescription opiates) within the past 6 months
- •Received any experimental drug within 30 days of enrollment at Visit 2; in the case of experimental protein therapeutics or vaccines, at least 6 months prior to enrollment
- •Other than oral contraceptives, use of prescribed medications or over-the-counter medications that in the opinion of the investigator might interfere with the study
- •Any medical condition, which, in the opinion of the study investigator, could adversely affect the patient’s participation in the trial, including the ability to tolerate two (2) upper gastrointestinal endoscopies with duodenal biopsies, or affect the trial integrity
- •Known allergy or hypersensitivity to any of the components of ALV003 (including sulfites), E. coli, or E. coli-derived proteins
- •Any study staff directly involved with the conduct of the study
研究者
相似试验
进行中（未招募）
1 期
A Phase 2b, Randomized, Double-Blind, PLacebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free DietMedDRA version: 17.0Level: LLTClassification code 10007864Term: Celiac diseaseSystem Organ Class: 100000004856Celiac DiseaseEUCTR2013-003660-31-NOAlvine Pharmaceuticals, Inc.500
进行中（未招募）
1 期
A Phase 2b, Randomized, Double-Blind, PLacebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free DietCeliac DiseaseEUCTR2013-003660-31-GBAlvine Pharmaceuticals, Inc.500
进行中（未招募）
不适用
A Phase 2b, Randomized, Double-Blind, PLacebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free DietMedDRA version: 16.1Level: LLTClassification code 10007864Term: Celiac diseaseSystem Organ Class: 100000004856Celiac DiseaseEUCTR2013-003660-31-FIAlvine Pharmaceuticals, Inc.500
进行中（未招募）
不适用
A Phase 2b, Randomized, Double-Blind,Placebo-Controlled, Safety and Efficacy Trial ofMultiple Dosing Regimens of ABT-719 for thePrevention of Acute Kidney Injury in SubjectsUndergoing High Risk Major SurgeryAcute Kidney InjuryEUCTR2012-005710-19-DKAbbVie Deutschland GmbH & Co. KG240
进行中（未招募）
1 期
Efficacy and Safety of ANB019 in Subjects with IchthyosisMedDRA version: 21.0Level: LLTClassification code 10037159Term: Psoriasis pustularSystem Organ Class: 100000004858IchthyosisEUCTR2020-003476-41-PLAnaptysBio Inc.24